BridgeBio Pharma, Inc. Financial Ratios — BBIO Stock

Profitability (USD)

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Return on Common Equity (%)	- -	- -	-72.05	-192.44	- -	- -	- -	- -	- -
Return on Assets (%)	- -	-46.45	-47.53	-67.21	-65.55	-58.83	-110	-73.11	-78.14
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Gross Margin (%)	- -	- -	93.84	100	95.53	95.58	73.71	98.25	95.82
EBITDA Margin (%)	- -	- -	-654.29	-5,734.34	-818.73	-594.56	-6,373.75	-257.45	-98.92
Operating Margin (%)	- -	- -	-656.41	-5,751.99	-827.12	-603.28	-6,443.56	-260.19	-100
Incremental Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Pretax Margin (%)	- -	- -	-711.5	-6,127.87	-841.2	-624.17	-7,021.94	-244.34	-145.89
Profit Margin (%)	- -	- -	-642.47	-5,439.74	-806.9	-619.7	-6,913.92	-241.44	-144.39
Net Income to Common Margin (%)	- -	- -	-642.47	-5,439.74	-806.9	-619.7	-6,913.92	-241.44	-144.39
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -
Dvd Payout Ratio (%)	-2.02	- -	-0.31	- -	- -	- -	- -	- -	- -
Sustainable Growth Rate (%)	- -	- -	-72.28	-192.44	- -	- -	- -	- -	- -

Credit (USD)

Credit Ratios API ChatGPT

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Total Debt	- -	55	100	496	1,726	1,724	1,740	1,731	1,862
ST Debt	- -	- -	8	5	5	4	4	5	6
LT Debt	- -	55	92	491	1,721	1,720	1,736	1,726	1,856
Total Debt/EBITDA	- -	-0.3	-0.38	-1.05	-3.02	-3.73	-2.93	-3.03	-3.75
Net Debt/EBITDA	2.11	2.08	1.02	-0.26	-2.3	-2.88	-2.28	-1.82	-2.58
Total Debt/EBIT	- -	-0.3	-0.37	-1.04	-2.99	-3.68	-2.9	-3	-3.71
Net Debt/EBIT	2.1	2.08	1.02	-0.26	-2.27	-2.84	-2.25	-1.8	-2.55
EBITDA to Interest Expense	-3,353.69	-72.11	-30.28	-12.9	-12.2	-5.74	-7.29	-5.75	-2.79
EBITDA-CapEx/Interest Expense	-3,389.38	-79.25	-30.58	-13.11	-13.23	-5.82	-7.31	-5.84	-2.84
EBIT to Interest Expense	-3,373.69	-72.11	-30.38	-12.94	-12.33	-5.82	-7.37	-5.81	-2.82
Interest Expense	- -	3	9	37	47	80	81	99	178
Common Equity/Total Assets	-60.02	67.72	64.66	8.23	-85.94	-201.37	-247.86	-159.67	-222.92
Long-Term Debt/Equity (%)	- -	14.44	19.28	454.68	- -	- -	- -	- -	- -
Long-Term Debt/Capital (%)	- -	12.62	15.94	81.26	200.01	359.33	436.87	632.33	-866.98
Long-Term Debt/Total Assets (%)	- -	11.72	14.53	69.72	169.95	276.05	317.67	187.75	198.32
Total Debt/Equity (%)	- -	14.44	20.97	459.55	-199.42	-138.45	-129.59	-118.73	-89.69
Total Debt/Capital (%)	- -	12.62	17.33	82.13	200.58	360.1	437.91	633.98	-869.88
Total Debt/Total Assets (%)	- -	11.72	15.8	70.47	170.44	276.64	318.43	188.24	198.98
Net Debt to Equity	168.23	-101.12	-57.14	112.37	-151.35	-106.91	-100.62	-71.37	-61.75
Net Debt/Capital (%)	62.72	9,048.59	-128.3	48.97	280.63	1,305.46	6,321.57	-254.89	-163.52
EBITDA	-44	-184	-265	-473	-571	-462	-593	-571	-497
EBITDA-CapEx	-44	-202	-268	-481	-619	-468	-594	-580	-506
Operating Income (Loss)	-44	-184	-266	-474	-577	-468	-599	-577	-502

Liquidity (USD)

Liquidity Ratios API ChatGPT

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Cash Ratio	10.76	13.39	9.04	6.35	6.19	3.89	3.02	4.41	2.04
Current Ratio	11.36	13.67	9.42	6.72	6.58	4.52	3.32	4.67	2.77
Quick Ratio	10.76	13.39	9.09	6.35	6.34	4.03	3.04	4.44	2.52
CFO/Avg Current Liab	- -	-6.64	-5.46	-5.12	-4.32	-3.27	-3.98	-3.49	-2.02
Common Equity/Total Assets	-60.02	67.72	64.66	8.23	-85.94	-201.37	-247.86	-159.67	-222.92
Long-Term Debt/Equity (%)	- -	14.44	19.28	454.68	- -	- -	- -	- -	- -
Long-Term Debt/Capital (%)	- -	12.62	15.94	81.26	200.01	359.33	436.87	632.33	-866.98
Long-Term Debt/Total Assets (%)	- -	11.72	14.53	69.72	169.95	276.05	317.67	187.75	198.32
Total Debt/Equity (%)	- -	14.44	20.97	459.55	-199.42	-138.45	-129.59	-118.73	-89.69
Total Debt/Capital (%)	- -	12.62	17.33	82.13	200.58	360.1	437.91	633.98	-869.88
Total Debt/Total Assets (%)	- -	11.72	15.8	70.47	170.44	276.64	318.43	188.24	198.98
CFO/Total Liabilities	-26.51	-156.02	-162.87	-67.1	-26.51	-22.46	-27.94	-21.91	-14.8
CFO/CapEx	-87.26	-7.52	-96.13	-53.17	-10.32	-66.37	-404.07	-58.46	-46.49
Altman's Z-Score	-1.27	-0.78	15.37	5.75	-2.25	-5.76	-7.66	-4.65	-3.52

Working Capital (USD)

Working Capital Ratios API ChatGPT

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Accounts Receivable Turnover	- -	- -	- -	- -	- -	- -	10.63	68.56	6.97
Days Sales Outstanding	- -	- -	- -	- -	- -	- -	34.35	5.32	52.4
Inventory Turnover	- -	- -	- -	- -	- -	- -	- -	- -	1.57
Days Inventory Outstanding	- -	- -	- -	- -	- -	- -	- -	- -	232.92
Accounts Payable Turnover	- -	- -	0.22	- -	0.3	0.29	0.22	0.38	2.08
Accounts Payable Turnover Days	- -	- -	1,632.35	- -	1,220.71	1,245.83	1,657.35	954.05	175.35
Cash Conversion Cycle	- -	- -	-1,632.35	- -	-1,220.71	-1,245.83	-1,623	-948.73	109.97
Inventory to Cash Days	- -	- -	- -	- -	- -	- -	34.35	5.32	-180.51
Inventories	- -	- -	- -	- -	- -	- -	- -	- -	27
Raw Materials	- -	- -	- -	- -	- -	- -	- -	- -	- -
Work In Process	- -	- -	- -	- -	- -	- -	- -	- -	- -
Finished Goods	- -	- -	- -	- -	- -	- -	- -	- -	- -
Other Inventory	- -	- -	- -	- -	- -	- -	- -	- -	27

Enterprise Value (USD)

Enterprise Value API ChatGPT

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Market Capitalization	- -	- -	4,334	8,736	2,458	1,148	7,068	5,215	14,898
- Cash & Cash Equivalents	92	436	364	356	394	377	376	681	570
+ Preferred Equity and Hybrid Capital	1	- -	- -	- -	- -	- -	- -	- -	- -
+ Minority/Non Controlling Interest	3	62	68	50	5	10	12	10	10
+ Total Debt	- -	55	100	496	1,726	1,724	1,740	1,731	1,862
Enterprise Value	-88	-319	3,956	8,674	3,352	2,409	8,385	6,275	16,183
Total Capital	-55	432	576	604	861	479	397	273	-214
Total Debt/Capital (%)	- -	12.62	17.33	82.13	200.58	360.1	437.91	633.98	-869.88
Total Debt / EV	- -	-0.17	0.03	0.06	0.51	0.72	0.21	0.28	0.12
EV/Sales	- -	- -	97.52	1,051.58	48.08	31.03	901.3	28.28	32.23
EV/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -
Diluted Market Cap	- -	- -	3,684	8,391	2,408	1,124	6,572	5,106	14,650
Diluted Enterprise Value	-88	-319	3,487	8,580	3,745	2,480	7,948	6,166	15,952
EV per Share	- -	- -	31.99	70.61	22.75	15.99	47.89	33.02	83.09
TTM Sales	- -	- -	41	8	70	78	9	222	502
TTM EBITDA	-44	-184	-265	-473	-571	-462	-593	-571	-497
TTM Operating Income	-44	-184	-266	-474	-577	-468	-599	-577	-502
TTM Cash Flow to Firm	-40	-134	-245	-363	-451	-339	-446	-421	-268
TTM Free Cash Flow to Firm	-40	-116	-242	-356	-403	-333	-445	-412	-258

Multiples (USD)

Valuation Multiples API ChatGPT

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Price/Free Cash Flow	- -	- -	-14.68	-21.39	-5.35	-2.72	-12.48	-9.98	-33.58
EV/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -
Enterprise Value	-88	-319	3,956	8,674	3,352	2,409	8,385	6,275	16,183
Low Price	- -	- -	17.61	14.23	11.2	4.98	7.1	21.62	27.53
EV/Sales	- -	- -	97.52	1,051.58	48.08	31.03	901.3	28.28	32.23
EV/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Earnings	- -	- -	- -	- -	- -	- -	- -	- -	- -
Price/Earnings Average	- -	- -	-11.17	-9.29	-13.98	-2.96	-5.4	-9.83	-12.26
Price/Earnings High	- -	- -	-19.5	-18.82	-18.86	-5.56	-11.22	-14.25	-20.72
Price/Earnings Low	- -	- -	-7.1	-3.74	-2.87	-1.53	-1.8	-7.51	-7.27
Price/Book Value	- -	- -	10.61	150.86	-2.82	-0.91	-5.22	-3.55	-7.14
Price/Book Value Average	- -	- -	8.38	74.99	-9.22	-1.16	-2.76	-3.66	-4.33
Price/Book Value High	- -	- -	14.64	151.82	-12.44	-2.18	-5.73	-5.31	-7.32
Price/Book Value Low	- -	- -	5.33	30.19	-1.9	-0.6	-0.92	-2.8	-2.57
Price/Tangible Book Value	- -	- -	10.61	150.86	-2.68	-0.89	-5.12	-3.5	-7.05
Price/Tangible Book Value Average	- -	- -	8.38	74.99	-8.77	-1.13	-2.71	-3.6	-4.27
Price/Tangible Book Value High	- -	- -	14.64	151.82	-11.83	-2.13	-5.62	-5.23	-7.22
Price/Tangible Book Value Low	- -	- -	5.33	30.19	-1.8	-0.58	-0.9	-2.75	-2.54
Price/Sales	- -	- -	90.82	1,017.17	34.54	14.47	706.43	23.01	29.18
Price/Sales Average	- -	- -	71.74	505.59	112.79	18.33	373.48	23.73	17.7
Price/Sales High	- -	- -	125.31	1,023.61	152.19	34.43	775.55	34.41	29.92
Price/Sales Low	- -	- -	45.63	203.55	23.19	9.46	124.24	18.13	10.5
Price/Cash Flow	- -	- -	-14.53	-20.99	-4.84	-2.68	-12.45	-9.81	-32.85
Price/Cash Flow Average	- -	- -	-11.47	-10.43	-15.79	-3.39	-6.58	-10.11	-19.93
Price/Cash Flow High	- -	- -	-20.04	-21.12	-21.31	-6.37	-13.67	-14.67	-33.69
Price/Cash Flow Low	- -	- -	-7.3	-4.2	-3.25	-1.75	-2.19	-7.73	-11.82
Price/Free Cash Flow Average	- -	- -	-11.6	-10.63	-17.49	-3.45	-6.6	-10.29	-20.37
Price/Free Cash Flow High	- -	- -	-20.25	-21.53	-23.59	-6.47	-13.71	-14.92	-34.43
Price/Free Cash Flow Low	- -	- -	-7.38	-4.28	-3.6	-1.78	-2.2	-7.86	-12.08
EV/Sales Average	- -	- -	79.56	549.39	134.31	36.2	549.54	29.01	20.6
EV/Sales High	- -	- -	142.6	1,088.71	174.52	52.64	981.97	39.92	33.02
EV/Sales Low	- -	- -	48.85	234.92	42.85	27.13	281.49	23.29	13.27
EV/EBITDA Average	2.01	1.74	-12.16	-9.58	-16.4	-6.09	-8.62	-11.27	-20.82
EV/EBITDA High	2.01	1.74	-21.79	-18.99	-21.32	-8.85	-15.41	-15.51	-33.39
EV/EBITDA Low	2.01	1.74	-7.47	-4.1	-5.23	-4.56	-4.42	-9.05	-13.42
EV/EBIT Average	2	1.74	-12.12	-9.55	-16.24	-6	-8.53	-11.15	-20.6
EV/EBIT High	2	1.74	-21.72	-18.93	-21.1	-8.73	-15.24	-15.34	-33.02
EV/EBIT Low	2	1.74	-7.44	-4.08	-5.18	-4.5	-4.37	-8.95	-13.27
Last Price	- -	- -	35.05	71.11	16.68	7.62	40.37	27.44	76.49
High Price	- -	- -	48.36	71.56	73.5	18.13	44.32	41.04	78.44
Enterprise Value Average	-88	-319	3,227	4,532	9,363	2,811	5,112	6,438	10,340
Enterprise Value High	-88	-319	5,784	8,981	12,167	4,087	9,135	8,859	16,580
Enterprise Value Low	-88	-319	1,981	1,938	2,987	2,107	2,619	5,169	6,664

Shares Outstanding	120	120	124	123	147	151	175	190	195
Diluted Weighted Avg Shares	92	92	105	118	144	147	163	186	192
Basic Weighted Avg Shares	92	92	105	118	144	147	163	186	192
Revenue per Share	- -	- -	0.39	0.07	0.48	0.53	0.06	1.19	2.62
EBITDA per Share	-0.47	-1.99	-2.53	-4.01	-3.95	-3.13	-3.64	-3.07	-2.59
Operating Income per Share	-0.48	-1.99	-2.53	-4.02	-3.99	-3.18	-3.68	-3.1	-2.62
Basic EPS, GAAP	-0.33	-1.42	-2.48	-3.8	-3.9	-3.26	-3.95	-2.88	-3.78
Basic EPS from Cont Ops	-0.47	-1.84	-2.75	-4.28	-4.06	-3.29	-4.01	-2.92	-3.83
Diluted EPS, GAAP	-0.33	-1.42	-2.48	-3.8	-3.9	-3.26	-3.95	-2.88	-3.78
Diluted EPS from Cont Ops	-0.47	-1.84	-2.75	-4.28	-4.06	-3.29	-4.01	-2.92	-3.83
Dividend per Share	0.01	- -	0.01	- -	- -	- -	- -	- -	- -
Cash Flow per Share	-0.44	-1.48	-2.41	-3.39	-3.45	-2.84	-3.24	-2.8	-2.33
Free Cash Flow per Basic Share	-0.44	-1.68	-2.44	-3.45	-3.78	-2.89	-3.25	-2.85	-2.38
Cash & Equivalents per Share	0.77	3.63	4.42	4.94	5.68	3.13	2.48	3.58	3.02
Book Value per Share	-0.49	2.62	3.3	0.47	-5.91	-8.33	-7.73	-7.72	-10.71
Tangible Book Value per Share	-0.49	2.62	3.3	0.47	-6.21	-8.52	-7.89	-7.85	-10.86

BridgeBio Pharma, Inc.

Profitability (USD)

Credit (USD)

Liquidity (USD)

Working Capital (USD)

Enterprise Value (USD)

Multiples (USD)

Per Share Data Items (USD)